Oxygen Self-Generating Nanoreactor Mediated Ferroptosis Activation and Immunotherapy in Triple-Negative Breast Cancer

被引:70
|
作者
Li, Ke
Xu, Kun [1 ]
He, Ye [2 ]
Yang, Yulu [1 ]
Tan, Meijun [1 ]
Mao, Yulan [1 ]
Zou, Yanan [1 ]
Feng, Qian [1 ]
Luo, Zhong [3 ]
Cai, Kaiyong [1 ]
机构
[1] Chongqing Univ, Minist Educ, Key Lab Biorheol Sci & Technol, Coll Bioengn, Chongqing 400044, Peoples R China
[2] Duke Univ, Thomas Lord Dept Mech Engn & Mat Sci, Durham, NC 27708 USA
[3] Chongqing Univ, Sch Life Sci, Chongqing 400044, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
self-supplying nanoreactor; ferroptosis; immunotherapy; O2; production; GSH depletion; triple-negative breast cancer; CELL-DEATH; THERAPY; HYPOXIA; NANOPARTICLES; HIF-1-ALPHA; RESISTANCE;
D O I
10.1021/acsnano.2c10893
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The hypoxia microenvironment of solid tumors poses a technological bottleneck for ferroptosis and immunotherapy in clinical oncology. Nanoreactors based on special physiological signals in tumor cells are able to avoid various tumor tolerance mechanisms by alleviating the intracellular hypoxia environment. Herein we reported a nanoreactor Cu2-xSe that enabled the conversion of Cu elements between Cu+ and Cu2+ for the generation of O2 and the consumption of intracellular GSH content. Furthermore, to enhance the catalytic and ferroptosis-inducing activities of the nanoreactors, the ferroptosis agonist Erastin was loaded on the ZIF-8 coating on the surface of Cu2-xSe to up-regulate the expression of NOX4 protein, increase the intracellular H2O2 content, catalyze the Cu+ to produce O2 and activate ferroptosis. In addition, the nanoreactors were simultaneously surface functionalized with PEG polymer and folic acid molecules, which ensured the in vivo blood circulation and tumor-specific uptake. In vitro and in vivo experiments demonstrated that the functionalized self-supplying nanoreactors can amplify the ability to generate O2 and consume intracellular GSH via the interconversion of Cu elements Cu+ and Cu2+, and impair the GPX4/GSH pathway and HIF-1 alpha protein expression. At the same time, by alleviating the intracellular hypoxia environment, the expression of miR301, a gene in the secreted exosomes was decreased, which ultimately affected the phenotype polarization of TAMs and increased the content of IFN gamma secreted by CD8+ T cells, which further promoted the ferroptosis induced by Erastin-loaded nanoreactors. This combined therapeutic strategy of activating the tumor immune response and ferroptosis via self-supplying nanoreactors provides a potential strategy for clinical application.
引用
收藏
页码:4667 / 4687
页数:21
相关论文
共 50 条
  • [11] Role of Immunotherapy in Triple-Negative Breast Cancer
    Keenan, Tanya E.
    Tolaney, Sara M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04): : 479 - 489
  • [12] Prospects of Immunotherapy for Triple-Negative Breast Cancer
    Qiu, Dan
    Zhang, Guijuan
    Yan, Xianxin
    Xiao, Xinqin
    Ma, Xinyi
    Lin, Shujun
    Wu, Jieyan
    Li, Xinyuan
    Wang, Wandi
    Liu, Junchen
    Ma, Yi
    Ma, Min
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [13] Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer
    Savas, Peter
    Loi, Sherene
    CANCER CELL, 2020, 37 (05) : 623 - 624
  • [14] Clinical trials of immunotherapy in triple-negative breast cancer
    Frederick M. Howard
    Alexander T. Pearson
    Rita Nanda
    Breast Cancer Research and Treatment, 2022, 195 : 1 - 15
  • [15] Clinical trials of immunotherapy in triple-negative breast cancer
    Howard, Frederick M.
    Pearson, Alexander T.
    Nanda, Rita
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (01) : 1 - 15
  • [16] Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer
    Elizabeth, Melendez Solano
    Cristina, Stevens Barron Jazmin
    Christian, Chapa Gonzalez
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (04) : 431 - 439
  • [17] Immunotherapy in Triple-Negative Breast Cancer: Present and Future
    Kim, Isaac
    Sanchez, Katherine
    McArthur, Heather L.
    Page, David
    CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 259 - 271
  • [18] Updates on the preoperative immunotherapy for triple-negative breast cancer
    Hu, Hong
    Kaklamani, Virginia
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [19] The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
    Michaels, Elena
    Chen, Nan
    Nanda, Rita
    CLINICAL BREAST CANCER, 2024, 24 (04) : 263 - 270
  • [20] Present and Future of Immunotherapy for Triple-Negative Breast Cancer
    Sriramulu, Sushmitha
    Thoidingjam, Shivani
    Speers, Corey
    Nyati, Shyam
    CANCERS, 2024, 16 (19)